Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven Stage IIIA(N2) nonsmall cell lung carcinoma

Autor: Cesare Gridelli, Olga Martelli, Luigi Portalone, Stefano Treggiari, Maria Rita Migliorino, Enrico Cortesi, Carlo Crispino, Fabrizio Nelli, Luigi Brancaccio, Filippo De Marinis
Rok vydání: 2003
Předmět:
Zdroj: Cancer. 98:1707-1715
ISSN: 1097-0142
0008-543X
DOI: 10.1002/cncr.11662
Popis: BACKGROUND The objective of the current study was to define the activity and tolerability, as well as the influence on resectability, of the combination of gemcitabine, paclitaxel, and cisplatin (GTP) as induction chemotherapy for patients with Stage IIIA(N2) nonsmall cell lung carcinoma (NSCLC). METHODS Forty-nine chemotherapy-naive patients (median age, 61 years; World Health Organization performance status, 0–1) with biopsy-proven Stage IIIA(N2) disease received 1000 mg/m2 gemcitabine, 125 mg/m2 paclitaxel, and 50 mg/m2 cisplatin on Days 1 and 8 of every 3 weeks until reevaluation for surgery or definitive radiotherapy. RESULTS Grade 3–4 neutropenia was the most common hematologic toxicity, occurring in 32.7% of patients; however, only 1 case of febrile neutropenia was reported. Grade 3–4 thrombocytopenia occurred in 12.2% of patients but was not associated with bleeding. Severe nonhematologic toxicities were uncommon; the only Grade 4 nonhematologic toxicity was diarrhea, which occurred in 4% of patients. One patient died after the first course of therapy, but this event was found to be unrelated to treatment. Thirty-six patients (73.5%) achieved an objective response, and an additional 4 patients had stable disease with clearance of mediastinal lymph nodes. Overall, 29 patients underwent thoracotomy and 27 (55%) underwent complete resection. Mediastinal nodes were free of tumor in 35% of all cases, and 8 pathologic complete responses (16%) were reported. Median survival was 23 months, with a 1-year survival rate of 85%. CONCLUSIONS GTP is highly active as an induction chemotherapy regimen for Stage IIIA(N2) NSCLC and yields good toxicity results. The use of GTP in combination with radiotherapy and new biologic drugs should be explored. Cancer 2003. © 2003 American Cancer Society. DOI 10.1002/cncr.11662
Databáze: OpenAIRE
Externí odkaz: